Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black
{"title":"The Clinical and Economic Burden of Idiopathic Hypersomnia: Results from the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) Study.","authors":"Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black","doi":"10.2147/NSS.S498432","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Limited research describes the clinical and economic burden of idiopathic hypersomnia. This study compared this burden in individuals with idiopathic hypersomnia against matched controls.</p><p><strong>Patients and methods: </strong>This retrospective cohort study analyzed Merative™ MarketScan<sup>®</sup> US claims (12/31/2013-2/29/2020). Individuals were ≥18 years of age and continuously enrolled during a 2-year assessment period. Individuals with idiopathic hypersomnia entered the cohort upon their first idiopathic hypersomnia medical claim; they were matched 1:5 with non-idiopathic hypersomnia controls on age, sex, region, insurance type, and cohort entry date. Odds of comorbid conditions experienced by individuals in either cohort during the 2-year assessment were compared. Healthcare resource utilization (HCRU) was presented as percentages by care setting. Median medical cost per patient per year (PPPY) was the sum of inpatient, outpatient, and emergency costs. <i>P</i>-values were not adjusted for multiplicity.</p><p><strong>Results: </strong>This analysis included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. In both cohorts, median age was 45 years and 65% of individuals were female. Compared with matched controls, individuals with idiopathic hypersomnia had 1.6- to 4.4-fold higher odds (all <i>P</i><0.0001) of grouped conditions defined by multilevel Clinical Classifications Software categories, from neoplasms to nervous systems diseases, including sleep-related conditions. Individuals with idiopathic hypersomnia had higher odds of all comorbid conditions evaluated, including sleep-related, cardiovascular and cardiometabolic, and neuropsychiatric conditions, compared with matched controls. Individuals with idiopathic hypersomnia had higher HCRU (outpatient, 100% vs 96.1%; emergency department, 46.6% vs 34.3%; inpatient, 10.2% vs 8.5%, all <i>P</i><0.0001) than matched controls. Median medical costs PPPY were higher for individuals with idiopathic hypersomnia ($4854) than matched controls ($1348).</p><p><strong>Conclusion: </strong>Compared with matched controls, individuals with idiopathic hypersomnia had a higher clinical burden, spanning multiple organ systems, and a higher economic burden. Individuals' clinical profiles may be considered when treating idiopathic hypersomnia and providing holistic care.</p>","PeriodicalId":18896,"journal":{"name":"Nature and Science of Sleep","volume":"17 ","pages":"1743-1755"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318847/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature and Science of Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/NSS.S498432","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Limited research describes the clinical and economic burden of idiopathic hypersomnia. This study compared this burden in individuals with idiopathic hypersomnia against matched controls.
Patients and methods: This retrospective cohort study analyzed Merative™ MarketScan® US claims (12/31/2013-2/29/2020). Individuals were ≥18 years of age and continuously enrolled during a 2-year assessment period. Individuals with idiopathic hypersomnia entered the cohort upon their first idiopathic hypersomnia medical claim; they were matched 1:5 with non-idiopathic hypersomnia controls on age, sex, region, insurance type, and cohort entry date. Odds of comorbid conditions experienced by individuals in either cohort during the 2-year assessment were compared. Healthcare resource utilization (HCRU) was presented as percentages by care setting. Median medical cost per patient per year (PPPY) was the sum of inpatient, outpatient, and emergency costs. P-values were not adjusted for multiplicity.
Results: This analysis included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. In both cohorts, median age was 45 years and 65% of individuals were female. Compared with matched controls, individuals with idiopathic hypersomnia had 1.6- to 4.4-fold higher odds (all P<0.0001) of grouped conditions defined by multilevel Clinical Classifications Software categories, from neoplasms to nervous systems diseases, including sleep-related conditions. Individuals with idiopathic hypersomnia had higher odds of all comorbid conditions evaluated, including sleep-related, cardiovascular and cardiometabolic, and neuropsychiatric conditions, compared with matched controls. Individuals with idiopathic hypersomnia had higher HCRU (outpatient, 100% vs 96.1%; emergency department, 46.6% vs 34.3%; inpatient, 10.2% vs 8.5%, all P<0.0001) than matched controls. Median medical costs PPPY were higher for individuals with idiopathic hypersomnia ($4854) than matched controls ($1348).
Conclusion: Compared with matched controls, individuals with idiopathic hypersomnia had a higher clinical burden, spanning multiple organ systems, and a higher economic burden. Individuals' clinical profiles may be considered when treating idiopathic hypersomnia and providing holistic care.
期刊介绍:
Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep.
Specific topics covered in the journal include:
The functions of sleep in humans and other animals
Physiological and neurophysiological changes with sleep
The genetics of sleep and sleep differences
The neurotransmitters, receptors and pathways involved in controlling both sleep and wakefulness
Behavioral and pharmacological interventions aimed at improving sleep, and improving wakefulness
Sleep changes with development and with age
Sleep and reproduction (e.g., changes across the menstrual cycle, with pregnancy and menopause)
The science and nature of dreams
Sleep disorders
Impact of sleep and sleep disorders on health, daytime function and quality of life
Sleep problems secondary to clinical disorders
Interaction of society with sleep (e.g., consequences of shift work, occupational health, public health)
The microbiome and sleep
Chronotherapy
Impact of circadian rhythms on sleep, physiology, cognition and health
Mechanisms controlling circadian rhythms, centrally and peripherally
Impact of circadian rhythm disruptions (including night shift work, jet lag and social jet lag) on sleep, physiology, cognition and health
Behavioral and pharmacological interventions aimed at reducing adverse effects of circadian-related sleep disruption
Assessment of technologies and biomarkers for measuring sleep and/or circadian rhythms
Epigenetic markers of sleep or circadian disruption.